ArticleFrontiers in medicine2026
Three-year longitudinal assessment of denosumab's efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Denosumab is an effective antiresorptive therapy for postmenopausal osteoporosis; however, long-term real-world data regarding sustained efficacy, treatment adherence, safety, and biochemical outcomes remain limited. This study evaluated the 36-month effectiveness and safety of denosumab in postmenopausal women with osteoporosis receiving routine clinical care. Methods: This retrospective analysis included a prospectively followed real-world clinical cohort of 130 postmenopausal women with osteoporosis treated with denosumab (60 mg subcutaneously every 6 months) plus calcium and vitamin D supplementation. Participants were followed for 36 months with assessments at baseline, 12, 24, and 36 months. Outcomes included bone mineral density (BMD), T-scores, bone turnover markers, renal function, adherence patterns, prior treatment history, fracture occurrence, and adverse events. Changes over time were analyzed using paired longitudinal comparisons and linear mixed-effects models, with significance defined as Results: Lumbar spine (L1-L4) BMD increased from 0.674 ± 0.120 to 0.741 ± 0.102 g/cm Conclusion: Thirty-six months of denosumab treatment was associated with sustained improvement in BMD, suppression of bone turnover, acceptable adherence, and a favorable safety profile in postmenopausal women with osteoporosis who completed the planned 36-month treatment course. Because only patients completing all seven injections with complete follow-up data were included, adherence, persistence, and safety outcomes may be overestimated compared with an intention-to-treat population. These findings support the effectiveness of denosumab under routine clinical practice while emphasizing the importance of continued monitoring and adherence management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.